You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 27, 2024

Details for Patent: 10,710,966

✉ Email this page to a colleague

« Back to Dashboard

Which drugs does patent 10,710,966 protect, and when does it expire?

Patent 10,710,966 protects OGSIVEO and is included in one NDA.

This patent has forty-two patent family members in sixteen countries.

Summary for Patent: 10,710,966

Patent landscape, scope, and claims:

Title:	Solid state forms of (S)-2-(((S)-6,8-difluoro-1,2,3,4-tetrahydronaphthalen-2-yl)amino)-N-(1-(2-methyl-1-(neopentylamino)propan-2-yl)-1H-imidazol-4-yl)pentanamide and uses thereof
Abstract:	The present disclosure relates to: a) solid state forms of hydrobromide salts of Compound 1; b) pharmaceutical compositions comprising one or more solid state forms of hydrobromide salts of Compound 1, and, optionally, a pharmaceutically acceptable carrier; c) methods of treating tumors or cancers by administering one or more solid state forms of hydrobromide salts of Compound 1 to a subject in need thereof; and d) methods for the preparation of solid state forms of Compound 1.
Inventor(s):	Greer Elaine, Anderson Stephen, Maloney Mark, Yu Shu, Albert Ekaterina, Rigsbee Emily
Assignee:	Pfizer Inc.
Application Number:	US16818863
Patent Claim Types: see list of patent claims
More… ↓ ⤷ Subscribe

Drugs Protected by US Patent 10,710,966

Subscribe to access the full database, or Subscribe
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Springworks	OGSIVEO	nirogacestat hydrobromide	TABLET;ORAL	217677-001	Nov 27, 2023		RX	Yes	No	10,710,966	⤷ Subscribe		Y		TREATMENT OF ADULT PATIENTS WITH PROGRESSING DESMOID TUMORS	⤷ Subscribe
Springworks	OGSIVEO	nirogacestat hydrobromide	TABLET;ORAL	217677-002	Apr 4, 2024		RX	Yes	No	10,710,966	⤷ Subscribe		Y		TREATMENT OF ADULT PATIENTS WITH PROGRESSING DESMOID TUMORS	⤷ Subscribe
Springworks	OGSIVEO	nirogacestat hydrobromide	TABLET;ORAL	217677-003	Apr 4, 2024		RX	Yes	Yes	10,710,966	⤷ Subscribe		Y		TREATMENT OF ADULT PATIENTS WITH PROGRESSING DESMOID TUMORS	⤷ Subscribe
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

International Family Members for US Patent 10,710,966

Subscribe to access the full database, or Subscribe
Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	119614	⤷ Subscribe
Australia	2019461090	⤷ Subscribe
Australia	2022342176	⤷ Subscribe
Australia	2022380837	⤷ Subscribe
Brazil	112022002392	⤷ Subscribe
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.